Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors

Royalty Pharma (RPRX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, RPRX crossed above the 20-day moving average, suggesting a short-term bullish trend.

Zacks Investment Research • Aug 13, 2026

Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million

NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma's economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder.

GlobeNewsWire • Aug 12, 2026

Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide

Company announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 million for the sale of its economic interests related to rusfertide, including royalty rights on the potential future global net sales of rusfertide.

GlobeNewsWire • Aug 12, 2026

Royalty Pharma Q2 Earnings Call Highlights

Royalty Pharma NASDAQ: RPRX raised its 2026 outlook for the second consecutive quarter after reporting higher second-quarter royalty receipts, continued capital deployment and progress across its development-stage pipeline.

MarketBeat • Aug 5, 2026

Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript

Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 5, 2026

Royalty Pharma reports second quarter 2026 results

Portfolio Receipts growth of 6% to $773 million; Royalty Receipts growth of 14% Net cash provided by operating activities of $728 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,400 million to $3,500 million NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. “Royalty Pharma delivered strong second quarter results with Royalty Receipts growth of 14%,” said Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of the Board.

GlobeNewsWire • Aug 5, 2026

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Royalty Pharma (RPRX) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.14 per share a year ago.

Zacks Investment Research • Aug 5, 2026

Royalty Pharma (RPRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Royalty Pharma (RPRX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Aug 5, 2026

Gear Up for Royalty Pharma (RPRX) Q2 Earnings: Wall Street Estimates for Key Metrics

Beyond analysts' top-and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

Zacks Investment Research • Aug 4, 2026

Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives

NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective August 2026. Greg will lead Royalty Pharma's outreach efforts with academic and non-profit institutions as well as oversee the Royalty Pharma Translational Prize. Greg joins Royalty Pharma after nearly three decades at the intersection of science, medicine and investing, and most recently served as Senior Vice President, Technology Development at Memorial Sloan Kettering Cancer Center.

GlobeNewsWire • Aug 3, 2026